Long-term Outcomes of Antiviral Therapy in Patients With Advanced Chronic HBV Infection

Hye Won Lee; Jun Yong Park; Sang Gyune Kim; Won Young Tak; Hyung Joon Yim; Byoung Kuk Jang; Moon Young Kim; Byung Ik Kim; Jin-Woo Lee; Ki Tae Yoon; Jae Youn Cheong; So Young Kwon; Tae Yeob Kim; Si Hyun Bae; Yeon Seok Seo; Jung Hyun Kwon; Dong Joon Kim; Ja-Kyung Kim; Soung Won Jeong; Sungmin Myoung; Sang Hoon Ahn; Kwang-Hyub Han; Soul Study Group

doi:10.1016/j.cgh.2019.01.044

Long-term Outcomes of Antiviral Therapy in Patients With Advanced Chronic HBV Infection

Clin Gastroenterol Hepatol. 2019 Dec;17(13):2811-2813.e1. doi: 10.1016/j.cgh.2019.01.044. Epub 2019 Feb 5.

Authors

Hye Won Lee¹, Jun Yong Park¹, Sang Gyune Kim², Won Young Tak³, Hyung Joon Yim⁴, Byoung Kuk Jang⁵, Moon Young Kim⁶, Byung Ik Kim⁷, Jin-Woo Lee⁸, Ki Tae Yoon⁹, Jae Youn Cheong¹⁰, So Young Kwon¹¹, Tae Yeob Kim¹², Si Hyun Bae¹³, Yeon Seok Seo⁴, Jung Hyun Kwon¹⁴, Dong Joon Kim¹⁵, Ja-Kyung Kim¹, Soung Won Jeong¹⁶, Sungmin Myoung¹⁷, Sang Hoon Ahn¹, Kwang-Hyub Han¹⁸; Soul Study Group

Affiliations

¹ Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.
² Department of Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, South Korea.
³ Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, South Korea.
⁴ Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea.
⁵ Department of Internal Medicine, Keimyung University College of Medicine, Daegu, South Korea.
⁶ Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, South Korea.
⁷ Department of Internal Medicine, Sungkyunkwan University College of Medicine, Kangbuk Samsung Hospital, Seoul, South Korea.
⁸ Department of Internal Medicine, Inha University School of Medicine, Incheon, South Korea.
⁹ Department of Internal Medicine, Pusan National University College of Medicine, Busan, South Korea.
¹⁰ Department of Internal Medicine, Ajou University School of Medicine, Suwon, South Korea.
¹¹ Department of Internal Medicine, Konkuk University School of Medicine, Seoul, South Korea.
¹² Department of Internal Medicine, Hanyang University Guri Hospital, Guri, South Korea.
¹³ Department of Internal Medicine, College of Medicine, Catholic University of Korea, Seoul, South Korea.
¹⁴ Department of Internal Medicine, Catholic University of Korea, Incheon St. Mary's Hospital, Incheon, South Korea.
¹⁵ Department of Internal Medicine, Hallym University College of Medicine, Chuncheon, South Korea.
¹⁶ Department of Internal Medicine, Soonchunhyang University College of Medicine, Seoul, South Korea.
¹⁷ Department of Medical Information and Administration, College of Health Science, Jungwon University, Goesan, South Korea.
¹⁸ Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea. Electronic address: gihankhys@yuhs.ac.

PMID: 30731195
DOI: 10.1016/j.cgh.2019.01.044

Abstract

Hepatitis B virus (HBV) suppression with nucleot(s)ide analogue therapy reduces the risk of hepatic decompensation and hepatocellular carcinoma (HCC) in patients with advanced liver disease.¹ In the present era of potent antiviral therapies, the prognostic significance of the serum HBV DNA level as a biological gradient has substantially diminished; the majority of treated patients achieve virologic suppression.^2,3 After control of viremia, a higher baseline fibrosis level is a useful predictor for disease progression.⁴ Few "prospective" studies on the effects of antiviral agents, especially in chronic hepatitis B (CHB) patients with advanced liver disease, have been reported.

Publication types

Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Antiviral Agents / therapeutic use*
Carcinoma, Hepatocellular / epidemiology*
Esophageal and Gastric Varices / etiology
Female
Guanine / analogs & derivatives*
Guanine / therapeutic use
Hepatitis B e Antigens
Hepatitis B, Chronic / blood
Hepatitis B, Chronic / complications
Hepatitis B, Chronic / drug therapy*
Humans
Lamivudine / therapeutic use*
Liver Cirrhosis / complications
Liver Cirrhosis / pathology
Liver Cirrhosis / physiopathology
Liver Neoplasms / epidemiology*
Male
Middle Aged
Splenomegaly / etiology
Thrombocytopenia / etiology
Viral Load

Substances

Antiviral Agents
Hepatitis B e Antigens
Lamivudine
entecavir
Guanine